511
Views
38
CrossRef citations to date
0
Altmetric
Review

Beneficial effects of Saccharomyces boulardii CNCM I-745 on clinical disorders associated with intestinal barrier disruption

, &
Pages 67-82 | Published online: 11 Feb 2019

Abstract

Intestinal barrier defects lead to “leaky gut syndrome”, defined as an increase in intestinal permeability that allows the passage of luminal content into intestinal tissue and the bloodstream. Such a compromised intestinal barrier is the main factor underlying the pathogenesis of inflammatory bowel disease, but also commonly occurs in various systemic diseases such as viral infections and metabolic syndrome. The non-pathogenic yeast Saccharomyces boulardii CNCM I-745 has demonstrated its effectiveness as a probiotic in the prevention and treatment of antibiotic-associated, infectious and functional diarrhea. Via multiple mechanisms of action implicated in intestinal barrier function, S. boulardii has beneficial effects on altered intestinal microbiota and epithelial barrier defects in different pathologies. The well-studied probiotic yeast S. boulardii plays a crucial role in the preservation and/or restoration of intestinal barrier function in multiple disorders. This could be of major interest in diseases characterized by alterations in intestinal barrier function.

Introduction

In the human body, the gastrointestinal tract represents the largest surface area exposed to the external environment. The intestinal epithelium has a dual function, acting on one hand as an exchange surface between luminal nutrients, molecules produced by the intestinal microbiota and intestinal tissue, and on the other hand as a barrier to prevent the entry of and protect the tissue from external harmful substances such as pathogenic toxins and antigens.Citation1 This barrier is formed by the interconnection of epithelial cells via the apical junctional complex and desmosomes.Citation2 Its disruption leads to an increased intestinal permeability that facilitates translocation of luminal contents into the intestinal tissue and bloodstream, a situation referred to as “leaky gut syndrome”.Citation3 A significant body of evidence indicates that such disruption plays a crucial role in intestinal diseases such as inflammatory bowel diseases (IBDs) and irritable bowel syndrome (IBS), but more research evidence highlights that it also occurs in certain systemic diseases, including type 2 diabetes, obesity and HIV infection. The maintenance of intestinal barrier integrity is essential to the preservation of gastrointestinal homeostasis and could be of major importance in the treatment of various diseases and in the prevention of severe complications.Citation3,Citation4 The lack of published studies on the beneficial effects of other strains of Saccharomyces boulardii prompted us to focus on a specific strain of Saccharomyces boulardii, CNCM I-745 (S. boulardii). We summarize the clinical effects of S. boulardii on intestinal barrier function in gastrointestinal and systemic diseases, followed by a discussion of the mechanisms by which S. boulardii modulates intestinal permeability.

Intestinal barrier function

The intestinal epithelium functions as a barrier, preventing and controlling the penetration of food and bacterial antigens into the tissue. At the same time, it has to be permeable to allow the translocation of nutrients, electrolytes and water. This intestinal permeability allows the exchange of solutes and fluids between the intestinal lumen and tissueCitation5 and is mediated by two pathways: the transcellular pathway, which is generally associated with the transport of solutes by specific transporters present in the cell membrane, and the paracellular pathway, which is associated with the transport of small molecules in the space between epithelial cells.Citation6 Permeability can be assessed by different techniques in vitro and in vivo, in animal and human studies, respectively. In vitro assessments include the measurement of transepithelial resistance (TER) or macromolecular flux in Ussing chambers, morphological measurements of tight junction (TJ) components, and measurement of the polyethylene glycol profile to characterize pore pathways. In vivo approaches consist of the oral ingestion of probes (lactulose/mannitol) followed by their measurement in urinary excretion.Citation5 The integrity of the intestinal barrier is essential for intestinal homeostasis and is maintained by the presence and correct functioning of several components ().

Figure 1 Role of the intestinal barrier components in a healthy gut and a leaky gut.

Notes: The top panels show the components of the intestinal barrier: the microbiota (pale yellow), mucus (dark yellow), the epithelial layer (pink) and the immune layer (gray). The bottom panels show the intestinal barrier on the crypt–villus axis. (A) The healthy gut is characterized by an intact intestinal barrier. Commensal bacteria secrete antimicrobial toxins, which protect against pathogenic invasion and SCFAs produced by bacterial fermentation and participate in the formation of tight junctions. The epithelial cells secrete a variety of endogenous molecules, such as antimicrobial proteins and mucins (mucin-2), which make up the mucus layer, and IAPs, which protect the tissue against luminal toxins. The epithelial cells also mediate selective permeability by the apical junctional complex formed by tight and adherens junctions and desmosomes. The immune components include plasmatic cells, which secrete IgA, and the dendritic cells, which sense the luminal environment. (B) The leaky gut is characterized by a damaged intestinal barrier. Microbial dysbiosis leads to the interaction of luminal pathogens with intestinal epithelial cells via the bacterial lipid structures. Attachment of pathogens to the epithelial surface impairs the apical junctional complex and increases the intestinal permeability. As a consequence, food particles, toxins and pathogens penetrate into the tissue and provoke an inflammatory response, resulting in cell apoptosis. Increased intestinal permeability also increases the secretion of electrolytes and ions into the lumen, resulting in diarrhea.
Abbreviations: IAP, intestinal alkaline phosphatase; LPS, lipopolysaccharide; M cell, microfold cell; SCFA, short-chain fatty acid.
Figure 1 Role of the intestinal barrier components in a healthy gut and a leaky gut.

Intestinal microbiota

Bacteria, fungi, archaea, viruses and protozoa compose the gut microbiota and inhabit the gastrointestinal tract. Bacteria are the major component of the human microbiota, with more than 400 species hosted by the human gut.Citation7 Gene sequencing data show that three phyla predominate in the human micro-biota (Bacteroidetes, Firmicutes and Actinobacteria), with a large diversity in bacterial species but functional homogeneity.Citation8 Freter et al showed that bacterial competition for nutrients and adhesion sites limits the colonization by external bacteria. Indeed, exogenous bacteria must have an ecological advantage, compared to residing bacteria, to occupy an ecological niche,Citation9 which reveals a barrier effect induced by microbiota. Bacteria also act as modulators of intestinal permeability. Escherichia coli Nissle 1917 increases the TER by stimulating the TJ protein zonula occludens-2 (ZO-2). By contrast, E. coli C25 increases intestinal permeability.Citation10,Citation11 In addition, the microbiota protects intestinal tissue by secreting into the intestinal lumen bacterial toxins, known as bacteriocins, that inhibit the growth of other bacteria, thus reducing bacterial invasion.Citation12 In addition, some bacteria transform primary into secondary biliary acids, which protect against some pathogens.Citation13 Short-chain fatty acids (SCFAs), produced by microbial fermentation, promote intestinal barrier function by enhancing TJ assembly and the establishment of the TER.Citation14 Together, these findings demonstrate the active role played by commensal bacteria in intestinal barrier integrity.

Mucus

The mucus is both a physical and a chemical barrier which spatially delineates the lumen from the epithelium by the presence of antimicrobial peptides and trefoil peptides.Citation15 The gastrointestinal mucus is mainly composed of highly glyco-sylated proteins called mucins, synthesized and secreted by goblet cells into the lumen, but also of carbohydrates, lipids and water. In humans, the major component is mucin-2, followed by the trefoil factor-3.Citation15,Citation16 These components confer the viscoelastic properties displayed by mucus, and in humans allow the formation of a two-layered mucus coat several hundreds of micrometers thick.Citation16,Citation17

Epithelium

Although single layered, the epithelium is the physical living boundary between exterior and interior. The passage of molecules and ions across the epithelium and the cohesion between cells are regulated by the presence of two types of junctional complexes: apical TJs and below them adherens junctions (AJs).Citation2 The TJs are multiprotein complexes that seal cells together, maintaining membrane polarity and regulating the selective paracellular permeability of ions, nutrients and water. Transmembrane proteins (occludins, claudins, junctional adhesion molecules and tricellulin) link to actin microfilaments by cytoplasmic proteins called zonula occludens (ZO-1, ZO-2 and ZO-3). Every component contributes towards the assembly and/or the maintenance of the TJ and plays a role in the regulation of intestinal barrier function.Citation6,Citation18,Citation19 AJs are localized below the TJs and participate in both the integrity of the epithelial layer and cell–cell communication. AJs consist of calcium-dependent transmembrane proteins, called cadherins, which interact via their C-terminal domain with scaffold proteins, p120-catenin and β-catenin. In the intestinal epithelium, the major component is E-cadherin. The anchorage of the E-cadherin/catenins complex with actin cytoskeleton is mediated by α-catenin.Citation20 Within the epithelial cells, the tightness of both TJs and AJs is regulated through signal transduction proteins, such as myosin light chain kinase (MLCK), RhoGTPases, protein kinase C (PKC) and mitogen-activated protein kinase (MAPK), in response to various stimuli.Citation21 The expression level of junctional proteins is also controlled by mechanisms including transcriptional and post-transcriptional regulation, transport or recycling at the cell membrane.Citation22

Lamina propria

Below the intestinal epithelium, the lamina propria contains immune cells and contributes toward protection against potentially harmful molecules or pathogens while tolerating the presence of commensal bacteria. One immune response is demonstrated by intestine-specific IgA, which is secreted by B cells and binds to microorganisms, forming a complex, which is cleared by bowel movement.Citation3 In case of infections, kinase signaling cascades are activated, which induce nuclear factor-κB (NF-κB), leading to the secretion of pro-inflammatory mediators including IL-6, IL-8, IL-12 and TNF-α.Citation23 The secretion of anti-inflammatory cytokines, such as IL-10, by T lymphocytes is crucial to maintain the balance between tolerance and immune response.Citation6

Disruption of intestinal barrier function

The entry of bacteria, food contaminants and luminal antigens through damaged intestinal epithelial cells (IECs), dendritic cells or microfold cells poses a risk to the maintenance of intestinal integrity ().Citation24 Intestinal barrier disruption induces a systemic inflammatory response and causes increased permeability, functional impairment and disease.Citation2 Intestinal alkaline phosphatases (IAPs) protect intestinal tissue against luminal endotoxins such as lipopolysaccharide (LPS) by dephosphorylation, resulting in a reduction of the inflammatory response.Citation25 Loss of intestinal integrity with increased permeability plays a major role in the pathogenesis of multiple intestinal and extraintestinal disorders (eg, IBD, IBS, viral or bacterial infections, obesity, type 2 diabetes and non-alcoholic steatohepatitis). Increased intestinal permeability can also be iatrogenic following treatment with antibiotics or NSAIDs, leading to leaky flux diarrhea. Different factors can increase intestinal permeability, including genetic alterations or abnormal regulation of TJ function, dysbiosis of microbiota and chronic inflammation.Citation26 Such TJ alterations can lead to the relocalization of TJ proteins or to their disruption by phosphorylation state regulation. For example, the phosphorylation of occludin is essential for a functional TJ complex.Citation27 TJ alterations also include indirect mechanisms implicating actin cytoskeleton reorganization.Citation22 Such actin cytoskeleton alterations occur through myosin light chain (MLC) phosphorylation by MLCK, alteration in RhoGTPase activity or PKC activation. In physiological conditions, MLCK regulates TJ dynamics but in pathological conditions, secretion of pro-inflammatory cytokines can induce MLCK activation and disruption of TJs.Citation21 For example, interferon-γ or TNF-α was found to induce protein relocation and MLC phosphorylation, which facilitated actin contraction and caused the opening of TJs and extension of the intercellular space.Citation28

Modulation of intestinal epithelial barrier function by the probiotic Saccharomyces boulardii CNCM I-745

Definition and properties of S. boulardii CNCM I-745

Saccharomyces boulardii CNCM I-745 (S. boulardii) is a non-pathogenic yeast discovered in 1923 by a French microbiologist in Indochina. It has since been widely used as probiotic in the prevention and treatment of gastrointestinal disorders. As a yeast, S. boulardii is distinct from bacterial probiotics, in particular because of its intrinsic resistance to antibiotic treatment.Citation29 In addition, S. boulardii can adapt to and survive in the gastrointestinal tract owing to its ability to grow at 37°C, and its resistance to low gastric pHCitation30,Citation31 and to bile acids.Citation30,Citation32,Citation33 Once in the gastrointestinal tract, S. boulardii reaches a maximum concentration within 2 days and is cleared in the stools within 3–5 days after oral administration.Citation32

Intestinal permeability alterations due to enteric pathogens and corrective effects of S. boulardii

The IECs act as a physical barrier via TJs to protect tissue from invasion by pathogens. The bacterial recognition occurs by pattern recognition receptors such as Toll-like receptors (TLRs).Citation34 The TLRs are type I membrane proteins that protect mucosal and commensal homeostasis but also induce adaptive immune signaling in response to bacterial invasion.Citation35 They bind a variety of bacterial lipid structures and bacterial cell wall components. For example, TLR-2 signaling enhances the TJ-associated barrier through activation of the PI3K/Akt pathway.Citation34,Citation36 During invasion, enteric pathogens (bacteria and viruses) use TJs as receptors to attach to the cell membrane in order to become internalized, or they disrupt the TJ first before penetrating into the tissue. Alterations in TJs are implicated in diarrhea through a “leaky flux” mechanism, which allows the passage of ions and water toward the lumen after the impairment of intestinal barrier integrity. The S. boulardii CNCM I-745 strain is registered in many countries for the treatment of diarrhea in adults and children. Its efficacy has been proven through many randomized clinical trials and its use recommended by numerous scientific societies.Citation37 S. boulardii owes its clinical efficacy to a wide variety of actions counteracting numerous pathogen-induced deleterious effects. The modes of action of S. boulardii can be summarized as follows:Citation38 1) luminal action, referring to the action of S. boulardii within the lumen: antitoxinic effect, notably against cholera toxin and E. coli LPS, antimicrobial activity, modulation of intestinal flora and metabolic activity; 2) trophic action at the villi, ie, secretion of digestion-enhancing enzymes and induction of host digestive enzymesCitation39 and 3) mucosal action, referring to the action of S. boulardii deeper within the mucosa, including anti-inflammatory activity. Altogether, the various modes of action of S. boulardii act in concert to counteract infections and to support barrier function and regeneration of damaged intestinal tissue. A broad spectrum of non-clinical data supports the beneficial effects of S. boulardii counteracting the pathogenicity of various pathogens ().

Table 1 Deleterious actions of pathogens in the gut and beneficial effects of S. boulardii CNCM I-745

E. coli

Enteropathogenic E. coli (EPEC) and enterohemorrhagic E. coli (EHEC) are pathogenic strains of attaching and effacing bacteria. The interaction between bacterial toxins and IECs leads to intestinal barrier disruption and intestinal permeability alterations.Citation40 This type of invasion (for E. coli strains HB101 and LF82) is followed by alterations in electrolyte transport, chloride secretion and diarrhea.Citation41,Citation42 In various intestinal cell models, pathogenic effector proteins delivered into enterocytes have caused TJ disruption by MLCK and PKC activation, and increased intestinal permeability.Citation21 EPEC and EHEC cause gastroenteritis, with different mechanisms being responsible for the increased intestinal permeability. More precisely, EPEC infection stimulates phosphorylation of MLC by MLCK, inducing TJ disruption and the stimulation of cytoskeletal contraction. This event causes a drop in TER and thus increased intestinal permeability. EPEC infection is also associated with an alteration of occludin distribution (shift from TJ to cytosol) by a dephosphorylation of this protein, essential to this localization in the TJ complex.Citation40 In contrast to EPEC, EHEC infection is promoted by an alteration in ZO-1 distribution.Citation43 In EHEC O157:H7, the regulation of the dynamic of the actin cytoskeleton is also impaired in the paracellular permeability via a PKC-dependent mechanism which inactivates the RhoA/Rac/Cdc42 pathway and in turn increases actomyosin contractility.Citation44 Furthermore, E. coli O157:H7 strain has been shown to induce secretion of pro-inflammatory cytokines (IL-8) mediated by MAPK and NF-κB activation.Citation45 IECs treated with S. boulardii before infection by EPEC strain E2348/69 display a reduced level of secreted pro-inflammatory cytokines and a preserved TJ structure due to the abolition of MLC phosphorylation.Citation4 Administration of S. boulardii in mice reduced C. rodentium strain DBS100-induced colitis by a decrease in intestinal permeability and a reduction in chloride secretion and mannitol flow.Citation46 S. boulardii also modulates bacterial attachment of 055B5 E. coli to enterocytes by secreting a 63 kDa alkaline phosphatase.Citation47 Endotoxins such as LPS are dephosphorylated by this phosphatase, causing a reduction in bacterial attachment and a 60% decrease in the TNF-α level in the bloodstream.Citation47

Shigella

Invasion by Shigella requires two events that decrease barrier function: TJ disruption and E-cadherin intracellular domain cleavage.Citation48 An increased intestinal permeability facilitates Shigella invasion into IECs, leading to bacterial dysentery. In T84 cells, modification of the phosphorylation status of occludin and reduction in claudin-1 expression mediated TJ disruption.Citation27 In both in vitro and in vivo models, S. boulardii has shown to restore partially this claudin-1 expression and the barrier integrity. It also exerted anti-inflammatory effects by inhibiting IL-8 secretion mediated by NF-κB and ERK1/2 phosphorylation.Citation49

Salmonella

Salmonella species belong to the family of proteobacteria. The subtype Salmonella enterica serovar Typhimurium is a major cause of gastroenteritis. Translocation of effector proteins is a key event in S. enterica Typhimurium invasion. Translocation is caused by decreased expression of ZO-1, modified phosphorylation status of occludin and activation of RhoGTPases. The resulting alteration in TJ and AJ localization causes a drop in TER as well as an increase in intestinal permeability, allowing bacterial invasion and amplified diarrhea.Citation28 Invasion by S. enterica Typhimurium also induces IL-8 secretion by NF-κB activation. S. boulardii protects mice during S. enterica Typhimurium infection and preserves epithelial barrier function in IECs. It was found to interfere with signaling pathways implicated in the invasion, in particular by reducing activation of RhoGTPases, which are implicated in actin cytoskeleton rearrangement and modulation of TJ proteins. It also decreased activation of MAPKs and reduced the level of inflammatory cytokines while up-regulating the secretion of anti-inflammatory cytokines such as IL-10 and TGF-β.Citation50,Citation51 In addition, S. boulardii adheres to S. enterica Typhimurium and, thus, prevents contact of the pathogen with the epithelial surface, decreasing the bacterial translocation to almost 50%.Citation51 Adhesion of S. enterica Typhimurium to yeast cells is mediated by type I fimbriae and this interaction uses mannose from yeast cell walls.Citation52 Furthermore, S. boulardii trapped S. enterica Typhimurium within the intestinal lumen, thereby deviating its trajectory and modifying its motility, thus increasing the fecal elimination of the pathogenic bacteria. These two mechanisms limit bacterial invasion.Citation53,Citation54 Intestinal epithelial barrier alterations have only been studied in animal models and need to be confirmed in humans.

Vibrio cholerae

V. cholerae is an enteropathogen responsible for cholera epidemics. Two toxins are produced: zonula occludens toxin, which alters the barrier function of TJs, and the 84 kDa enterotoxin cholera toxin, which modulates membrane channels. Cyclic adenosine monophosphate (cAMP) stimulation resulting from toxin catalytic activity induces chloride secretion into the intestinal lumen and causes hydroelectrolytic diarrhea.Citation55 Cell adhesion leakage allows the diffusion of water and ions into the lumen, causing diarrhea. A pre-incubation with S. boulardii was shown to dose-dependently decrease the cAMP level by up to 50% in male rats and rat epithelial intestinal cell lines (IRD 98 and IEC 17). The preventive role of S. boulardii is mediated by secretion of a 120 kDa protein which interferes with the cAMP-dependent induction of chloride secretion and decreases diarrhea caused by V. cholerae.Citation56,Citation57 Pretreatment by S. boulardii was shown to reduce intestinal damage and lesions in a rat model of V. cholerae infection.Citation58

Rotavirus

Rotavirus infection is associated with a drastic reduction in TER (from 325 to 22 Ω.cm2 in 24 hours).Citation34 An increase in intestinal permeability stems from a deregulated secretion and absorption of ions. Thus, noxious substances can penetrate into the intestinal tissue, inducing diarrhea and morbidity.Citation35 Rotavirus produces the enterotoxin non-structural protein-4 (NSP-4), which alters the localization of TJ proteins (ZO-1, occludin and claudin-3), leading to the disruption of intestinal barrier integrity and blockade of epithelial barrier formation in MDCK cells.Citation59 In addition, NSP-4 alters redox balance by enhancing ROS production in the mitochondrial compartment of enterocytes, with the potential to cause damage to intestinal barrier integrity. The generation of ROS also induces chloride secretion and diarrhea. In a study with infected IECs, S. boulardii restored glutathione levels, which in turn inhibited ROS production, leading to a decrease in intestinal permeability.Citation60

Intestinal permeability alterations due to antibiotics and preventive and corrective effects of S. boulardii

While antibiotic treatment does result in the destruction of pathogens, it also destroys commensal bacteria, leading to osmotic diarrhea and the promotion of intestinal permeability, associated with potential bacterial and viral translocation. The S. boulardii CNCM I-745 strain has proven efficient in the prevention of such antibiotic-induced diarrhea, independent of the specific antibiotic ().Citation39,Citation61 In addition, by reducing the occurrence of diarrhea, S. boulardii is an effective adjunctive therapy for H. pylori eradication during antibiotic treatment.Citation62 Owing to its multiple modes of action, it is also effective in the treatment of Clostridium difficile infection and in the reduction of recurrence.Citation39 Finally, concomitant treatment by S. boulardii was recently shown to prevent the huge shifts in the microbiome composition observed following use of antibiotics alone.Citation63 Infection by C. difficile, responsible for diarrhea or even pseudomembranous colitis, can occur further to antibiotic treatment (). It is associated with frequent stools of liquid consistency during or after the antibiotic treatment, and sometimes a fever. Some evidence suggests a higher incidence of C. difficile infections among older adults, in particular those with multiple associated pathologies.Citation64 This kind of infectious diarrhea has a high risk of relapse even in the absence of antibiotic retreatment. C. difficile produces two toxins (A and B; enterotoxin and cyto-toxin, respectively) which alter the assembly and maturation of TJs.Citation65 Such TJ alterations lead to a reduction in TER and an increase in intestinal permeability, a key element in the pathological progression, as reflected by antibiotic-associated diarrhea (30% of cases) or pseudomembranous diarrhea (95%).Citation66,Citation67 In hamsters and gnotobiotic mice, S. boulardii reduced the rate of clindamycin-induced mortality caused by pseudomembranous colitis or C. difficile infection. The reduction in mortality was highest when S. boulardii was administered preventively.Citation68Citation70 These effects were correlated with a reduction in the number of C. difficile bacteria as well as a lowered toxin expression.Citation71 Moreover, S. boulardii was found to increase the concentration of IgAs directed against bacteria by 57%,Citation72 induce proteolysis of toxins A and B, and inhibit the interaction with enterocytes by secretion of a 54 kDa serine protease.Citation73,Citation74 This serine protease blocks JNK and ERK1/2 kinase activation, inhibits MLC phosphorylation and prevents TJ disruption. S. boulardii secretes another factor, named S. boulardii anti-inflammatory factor (SAIF; <1 kDa), which exerts anti-inflammatory effects by blocking NF-κB activation and IL-8 secretion mediated by IL-1β.Citation75 Altogether, S. boulardii-secreted factors exert anti-inflammatory and barrier-protective/restorative effects.

Figure 2 Proposed model for the effects of S. boulardii on intestinal permeability due to antibiotics.

Notes: Administration of antibiotics leads to multiple intestinal alterations. For example, antibiotic administration reduces all bacterial growth and this reduction leads to C. difficile growth and to the production of these toxins, which alter the formation of tight junctions. Intestinal permeability and the entry of pathogens into the lamina propria lead to different responses from the intestinal tissue: passage of electrolytes and water to the lumen, TNF-α production by macrophages leading to enterocyte apoptosis, and secretion of pro-inflammatory cytokines leading to inflammation. S. boulardii has a variety of preventive and corrective effects on antibiotic alterations: it stimulates the secretion of IgA directed against toxin A, and inhibits pathogen growth and toxin production. Besides, S. boulardii inhibits MLC phosphorylation and preserves the tight junction at the cell membrane. The restoration of intestinal barrier decreases the passage of electrolytes and water to the lumen. S. boulardii induces proteolysis of toxins A and B by secretion of serine protease (54 kDa) and secretes a factor named SAIF which exerts anti-inflammatory effects.
Abbreviations: C. difficile, Clostridium difficile; MLC, myosin light chain; NF-κB, nuclear factor-κB; S. boulardii, Saccharomyces boulardii; SAIF, S. boulardii anti-inflammatory factor.
Figure 2 Proposed model for the effects of S. boulardii on intestinal permeability due to antibiotics.

Gut response during childhood

Children’s gut responses to noxious agents are very different from adults’ because of the immaturity of the intestinal epithelial barrier in children. The development of the intestinal epithelial barrier occurs in utero and postnatally with the formation of AJ complexes, and then with the development of physical and chemical barriers (eg, defensins, lysozymes and mucins). The development in utero and the maturation postnatally are under the control of multiple factors, especially the development of the microbiota.Citation76 The first colonizers create a new environment that promotes colonization, such as Bacteroides, Clostridium and Bifidobacterium.Citation77 For many years, it was thought that uterine life was sterile and that newborns acquired a microbiota during delivery. In the past decade, investigations have shown bacterial transmission through the placental barrier and have detected bacteria in the placenta, umbilical cord blood, amniotic fluid and fetal membranes.Citation78Citation81 These findings suggest that the placenta is not sterile and that mother-to-child efflux of commensal bacteria exists, which influences both the microbiota and the immune system in utero. It is currently held that the maturation of microbiota begins during delivery and ends at 3 years old, at which timepoint it achieves the adult characteristics. During the maturation stage, several environmental factors may influence and affect the establishment and diversity of intestinal microbiota, including gestational age, mode of delivery (vaginal or cesarean), diet (breast milk or formula) and antibiotic treatment.Citation82 It has been reported that birth mode influences the level of bacterial species in the first 6 months until complete maturation of the microbiota.Citation83 Yassour et al described the influence of birth mode on the diversity and maturation of microbiota in 39 children aged 3–36 months. They observed multiple similarities in the composition of microbiota over time between birth modes (succession of bacterial populations in the gut communities); they also found a distinct microbial signature of Bacteroides in the first 6 months in babies born by cesarean section compared to vaginal delivery.Citation83 This can be explained by the fact that cesarean delivery transfers a large part of the commensal bacteria from the skin microbiota instead of the vaginal and fecal microbiota. Cesarean delivery increases by 20% the risk of acute gastroenteritis, and this risk is increased by 62–78% when cesarean section is combined with preterm delivery and exclusive formula feeding.Citation84

Diet is another major factor that influences the development of the microbiota. Investigations have shown that breastfeeding influences the growth of microbes and improves the intestinal barrier.Citation85 Components of the breast milk may improve the epithelial intestinal barrier and stimulate the immune system.Citation86

Other substances, such as prebiotic and probiotic compounds, may stimulate the production of various immunoglobulins (IgG, IgM and secretory IgA).Citation84 The development of a mature immune system is correlated with the development of the microbiota.Citation87 The SCFAs produced by microbes can affect the inflammatory response by binding to and stimulating G-protein coupled receptor-43 (GPR43).Citation88 The presence of Bacteroides fragilis in commensal bacteria is capable of suppressing inflammation by down-regulation of IL-17. It can also convert CD4+ T cells in regulatory T cells, which produce an anti-inflammatory cytokine (IL-10).Citation89 Exposure to postnatal antibiotics, total parental nutrition and delay in breastfeeding are factors responsible for the impairment of intestinal colonization and favor the overgrowth of pathological microorganisms.Citation90Citation93 Disruption of the gut barrier accompanied by altered microbiota and/or intestinal inflammation with impaired immune-regulatory mechanisms has been shown in many gastrointestinal diseases with onset in childhood (eg, celiac disease,Citation94 IBD and infectious diarrhea) but also in numerous extraintestinal pathological, noncommunicable diseases (eg, asthma, allergy, eczema, diabetes and cystic fibrosis with cirrhosis).Citation80,Citation95Citation100 Furthermore, several studies have shown that the gut microbiota has a role in the development of non-communicable diseases. Some bacteria are correlated with the onset of allergy, eczema or type 1 diabetes while others protect against these pathologies. For instance, Lactobacilli, Bacteroidetes, Bifidobacteria and Proteobacteria taxa are decreased in children who develop allergy.Citation88,Citation96,Citation101 With regard to non-communicable diseases, meta-analyses of clinical trials using probiotics for allergy prevention demonstrate a reduced incidence of eczema, but mechanistic pathways to understand how probiotics mediate these beneficial effects are still to be investigated. Furthermore, no studies have analyzed the effectiveness of S. boulardii in non-communicable diseases.Citation95

Only a few studies have specifically focused on the effects of S. boulardii on gut permeability in children. One important difference between bacteria and yeast is their cell wall composition, which is responsible for the modulation of the mucosal immune response.Citation29 In children with acute gastroenteritis, Ozkan et al showed that blood levels of IgA and of CD8 lymphocytes increased at day 7 while both C-reactive protein and complement C4 decreased in reaction to S. boulardii treatment.Citation102 These modifications in blood immune parameters are in line with the findings of Caetano et al in adults.Citation103

Leaky gut in gastrointestinal diseases

Luminal contents, diarrhea, dysbiosis and allergy can cause damage to IECs and lead to alterations in cell–cell junctions and finally to impaired intestinal permeability, known as the “leaky gut”. The leaky gut allows molecules, drugs or toxins to penetrate into the bloodstream and create chronic inflammation and further increases in intestinal permeability. This condition is responsible for many complications in gastrointestinal disorders, such as diarrhea or IBS, but also in non-gastrointestinal diseases. For example, the leaky gut observed in HIV patients can lead to cardiovascular disease or chronic kidney disease. In obesity, intestinal permeability can induce visceral obesity and/or type 2 diabetes.Citation27 More precisely, alterations in intestinal function are associated with the pathogenicity of type 2 diabetes. Several causes are responsible for the decrease in intestinal barrier in type 2 diabetes. Among them, changes in the dietary composition (from high carbohydrates to western diet) are important factors which allow a rapid modification of the microbiota community.Citation104 The nutritional imbalance along with changes in microbiota composition/activity contributes to the increase in intestinal permeability. The paracellular permeability allows the passage of bacterial lipoproteins such as LPS and their binding to TLR-4. Secretion of pro-inflammatory cytokines is induced after the activation of TLRs. The inflammatory cascade promotes the phosphorylation of the receptor insulin substrate and impairs insulin signaling.Citation105

Intestinal permeability is also believed to play a crucial role in some liver diseases, such as alcoholic or non-alcoholic steatohepatitis, cirrhosis and hepatocellular carcinoma.Citation106,Citation107

IBDs

IBDs are multifactorial diseases with two main subtypes: Crohn’s disease (CD) and ulcerative colitis (UC). The etiology is still unknown but IBDs are driven by an immune activation against the host microbiota in genetically predisposed patients.Citation108 IBDs have a prevalence of 1/1,000 and clinical morphological features that differ between CD and UC.Citation109 The microbiota (composition and diversity) and environmental factors are important in the pathogenesis of either IBD subtype.Citation110 While smoking increases the frequency of CD relapse, it shows no effect in UC patients. While all UC patients display AJ abnormalities, only 50% of patients with CD show such abnormalities. Impairment of intestinal permeability causes “leaky flux” diarrhea and an easier uptake of noxious substances, which could be of importance in IBD patients suffering from transit disorders and abdominal pain despite complete mucosal healing of their intestinal disease.Citation111 Alterations in intestinal barrier integrity cause a deregulation in the immune response with secretion of pro-inflammatory cytokines.Citation112 The impact of probiotics, including S. boulardii, in IBDs has been rigorously studied, with controversial results to date. A clinical study with 159 IBD patients treated with steroids or salicylates showed no significant effects of S. boulardii regarding CD relapse rate;Citation113 however, S. boulardii was effective on intestinal permeability, as shown by the decrease in the lactulose/mannitol ratio (33.33%).Citation114 Experimental studies on the effect of S. boulardii supernatant on mucosal lesions found that it accelerates the migration of enterocytes compared to control conditions by modulating α2β1- and αVβ5-integrin activation states.Citation115,Citation116 Another study showed, both ex vivo and in vitro, that S. boulardii accelerates the expression of E-cadherin at the cell membrane by inducing E-cadherin recycling in Rab11A-dependent recycling endosomes.Citation20 These experimental studies indicated that S. boulardii could have beneficial effects in the treatment and prevention of intestinal permeability in patients with IBDs.

IBS

IBS is a functional gastrointestinal disorder affecting more than 10% of the population across the world.Citation117 It is defined by the Rome IV criteria and characterized by intermittent abdominal pain, transit disorders such as diarrhea, constipation or alternating diarrhea/constipation, and is associated with bloating during the symptomatic periods. While no detectable structural or biochemical abnormalities have been found and despite many studies on motility, psychology, diet, visceral hypersensitivity and microbiota in IBS patients, the physiopathology remains unclear.Citation118 Nevertheless, some evidence does suggest the involvement of interactions between the gut, immune system and nervous system in the pathogenesis. In addition, increased intestinal permeability has been noted in patients with IBS, associated with a lower expression of ZO-1 and a decrease in TER.Citation119,Citation120 Increased intestinal permeability can contribute to more severe symptoms and hypersensitivity. In a mouse model, TJ alterations were found to originate from MLCK-dependent activation. While IBS is not lethal, patients do suffer from an altered quality of life and have increased health care costs. Clinical trials on probiotic efficiency have given controversial results. Some have suggested that S. boulardii can restore intestinal epithelial barrier function in IBS patients by modulating the intestinal immune response.Citation121 This could affect IBS symptoms and the hypersensitivity associated with an impaired intestinal barrier. These results need to be validated in larger studies.

The gut microbiota plays a major role in the pathogenesis of IBD and IBS. A dysbiosis characterized by an decrease in protective species and correlated with an increase in inflammatory species has been found in the mucosa and feces of IBD patients. Even if probiotics, and especially S. boulardii, do represent a plausible treatment, further studies are necessary to better characterize the exact role of S. boulardii in IBD and IBS and its specific mechanisms of action, including the modulation of microbiota. More evidence on the beneficial effects of S. boulardii in IBD and IBS needs to be validated with further placebo-controlled clinical studies.

New pathways to prevent intestinal permeability alterations in obesity and metabolic syndrome

The composition of the diet has a critical role in the colonization, maturation and stability of the microbial community. Dietary changes induce changes in the microbiota and lead to negative effects such as dysbiosis and low-grade inflammation. In non-obese humans, overfeeding leads to rapid changes in the composition of the gut microbiota and decreases nutrient absorption.Citation122 High-fat or high-sugar diets modify the composition of the microbiota by increasing the proportion of Firmicutes and reducing the proportion of Bac-teroidetes.Citation123 Furthermore, a western diet can have long-term consequences and can lead to the permanent loss of bacteria and induce inheritable metabolic changes.Citation124 Obesity is associated with chronic diseases such as diabetes, cardiovascular disorders and liver diseases. These pathologies are induced by a high-fat, high-sugar diet and are characterized by low-grade inflammation and the secretion of pro-inflammatory factors such as TNF-α or IL-1β, which in turn enhance the dysbiosis associated with intestinal permeability.

Impairments of epithelial barrier function are correlated with alterations in the structure and localization of TJ proteins, ZO-1 and occludin.Citation125 In addition, an imbalance in the Firmicutes/Bacteroidetes ratio contributes to alterations in the expression of TJ proteins.Citation126 In “leaky gut” patients, modifications of the intestinal microbiota composition lead to metabolic endotoxemia and to the translocation of com-mensal bacteria or bacterial products such as LPS into the circulation, contributing to a chronic systemic low-grade inflammation.Citation127

In a preclinical study evaluating the impact of S. boulardii on obesity, S. boulardii administered daily to 6-week-old obese, type 2 diabetic mice (db/db) for 4 weeks led to reductions in body weight, fat mass, hepatic steatosis and secreted pro-inflammatory cytokines (IL-1β, -4 and -6). In addition, S. boulardii was found to alter the microbial composition of the gut-affecting bacterial species known to be associated with diabetes, inflammation and intestinal permeability. This may have contributed to restoring intestinal barrier function.Citation128 However, in humans results are rare and inconsistent. Further investigations are required to determine whether S. boulardii has beneficial effects in the treatment of obesity and type 2 diabetes.

Excessive alcohol consumption is associated with alcoholic liver diseases (steatosis, acute alcoholic hepatitis and cirrhosis) and can lead to hepatocellular carcinoma. Alcohol was found to decrease the level of defensins, the expression of TJs and the number of immune cells within the intestinal wall.Citation129 Such defects associated with hepatic “micro-inflammation” play a role in the pathogenicity of liver diseases and bacterial translocation. In addition, a newly identified regulator of intestinal permeability (FoxO4) is increased by alcohol.Citation130 The relationship between intestinal permeability and liver disease is still speculative, and any factor found to restore intestinal barrier function could be of interest. Methionine–choline-deficient diet-induced non-alcoholic steatohepatitis in a mouse model highlights that gut micro-biota and overnutrition are other major factors involved in the pathogenicity of non-alcoholic fatty liver disease. The use of probiotics in that case prevents liver steatosis and inflammation induced by the diet and improves high-fat diet-induced insulin resistance and steatosis.Citation131

Leaky gut due to enteral feeding

Enteral nutrition is responsible for major changes in intestinal nutrient uptake. These changes produce a deficiency in SCFAs, which are known to participate in TJ assembly, and thus SCFA deficiency contributes to a loss of epithelial barrier function and alterations in intestinal permeability.Citation132 In a mouse model, enteral nutrition was associated with reduced expression of E-cadherin and β-catenin.Citation133 In addition, reduced SCFA levels caused diarrhea, the most frequent complication observed in ill, tube-fed patients. Schneider et al showed that treatment with S. boulardii increased the total fecal content of SCFAs, mostly in terms of butyrate level, in patients receiving long-term enteral nutrition (150.2±27.2 vs 107.5±18.2 mmol/kg, P=0.02) but not in controls (129±28.6 vs 113±15.2 mmol/kg, not significant).Citation132 An absence of luminal nutrition is associated with deleterious consequences to the intestinal barrier. In human intestinal Caco-2 cells, butyrate promoted barrier function by increasing AMP-activated protein kinase activity, accelerating TJ assembly and inhibiting NF-κB activation.Citation14 By increasing SCFA concentrations in patients with enteral nutrition, S. boulardii was shown to contribute to the restoration of the intestinal epithelial barrier, thereby preventing diarrhea in these patients.

Leaky gut in immunocompromised HIV patients

About 50–60% of HIV patients in western countries suffer from diarrhea. In HIV patients, the HIV envelope glycoprotein gp120 induces a reduction in intestinal TER. In addition, HIV caused alterations in TJ protein expression (claudin-1, occludin and ZO-1) and induced a pro-inflammatory response (IL-1, IL-6 and TNF-α), resulting in increased intestinal permeability.Citation134 Impairment of intestinal barrier function causes increased entry of LPS into the bloodstream along with a systemic immune activation, but also contributes to the translocation of HIV into tissue, both leading to faster disease progression.Citation134 Recent studies have focused on developing therapies that control bacterial translocation by decreasing intestinal permeability. In a double-blind, random-ized, placebo-controlled trial, Villar-García et al assessed the impact of S. boulardii on microbial translocation. Among 44 antiretroviral therapy-treated patients receiving S. boulardii or placebo for 12 weeks, supplementation with S. boulardii significantly decreased serum levels of LPS and IL-6, which are responsible for pore-forming claudin-2 expression.Citation135,Citation136 After 12 weeks of treatment, patients receiving S. boulardii showed increased levels of Megamonas and Desulfovibrionales species and decreased levels of certain pathogenic species (Clostridiales and Catenibacterium) known to correlate with IL-6 and TNF-α secretion.Citation135,Citation137 Analysis of the micro-biota profile by 16s rDNA did not establish the mechanisms underlying the modulation of gut microbiota by S. boulardii, but these data suggest that rather than acting directly on TJ barrier function, S. boulardii instead modulated the intestinal microbiota composition. More precisely, it is known that TNF-α and Il-6 secretion increases intestinal permeability through mechanisms involving TJs. IL-6 impairs ZO-1 apical localization and increases actin cytoskeleton contraction.Citation138 TNF-α increases MLCK protein levels and RhoA activation, correlated with an increase in intestinal permeability.Citation138 The change in microbial community after S. boulardii treatment restores a homeostatic microbiota and reduces pathogenic-related species.Citation139 Moreover, S. boulardii restored the production of certain SCFAs (acetate and propionate) to normal levels in an ex vivo model of the pig fecal microbial ecosystem disturbed by clindamycin.Citation140 We can speculate that S. boulardii has similar effects on the microbiota in HIV patients. Further studies are needed to explore the role of S. boulardii in TJ function in HIV infection, while taking into account the safety warning regarding the use of probiotics in patients with central venous catheters and in immunocom-promised or critically ill patients. Modifications in bacterial diversity and the reduction of pro-inflammatory cytokines by S. boulardii may restore intestinal barrier and prevent microbial translocation in HIV patients.

Conclusion

The intestinal epithelial barrier plays a major role in tissue defense and intestinal homeostasis. Disruption of this barrier is a key element in various gastrointestinal disorders and systemic diseases, and occurs through complex cross-talk between signaling pathways and TJ/AJ complex regulation. Understanding the mechanisms implicated in intestinal permeability is essential for the development of new therapeutics that may prevent or restore intestinal epithelial barrier function. Saccharomyces boulardii CNCM I-745, already used in the prevention and treatment of diarrhea of differing etiology (antibiotic-associated or infectious), has proven protective effects on the barrier function in various diseases. In this review, we have summarized the impact of S. boulardii on various gastrointestinal and systemic diseases associated with intestinal epithelial barrier defects. Through anti-inflammatory, anti-secretion, pro-migratory and adhesive effects, S. boulardii preserves and restores intestinal barrier function. Possibly, a yeast-induced general metabolic activation may enhance barrier function by the acceleration of enterocyte turnover.

This review opens new perspectives for various pathologies associated with impaired gut permeability, in which S. boulardii treatment could be investigated.

Author contributions

All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; gave final approval of the version to be published; and agree to be accountable for all aspects of the work.

Abbreviations

AJ=

adherens junction

cAMP=

cyclic adenosine monophosphate

CD=

Crohn’s disease

EHEC=

enterohemorrhagic Escherichia coli

EPEC=

enteropathogenic Escherichia coli

IAP=

intestinal alkaline phosphatase

IBD=

inflammatory bowel disease

IBS=

irritable bowel syndrome

IEC=

intestinal epithelial cell

LPS=

lipopolysaccharide

MAPK=

mitogen-activated protein kinase

MLC=

myosin light chain

MLCK=

myosin light chain kinase

NF-κB=

nuclear factor-κB

NSP-4=

non-structural protein-4

PKC=

protein kinase C

SAIF=

Saccharomyces boulardii anti-inflammatory factor

SCFA=

short-chain fatty acid

TER=

transepithelial resistance

TJ=

tight junction

TLR=

Toll-like receptor

UC=

ulcerative colitis

ZO-1=

zonula occludens-1

Acknowledgments

This review has received research funding from Biocodex, France. This manuscript has been edited by an independent scientific language service (Angloscribe, Calvisson, France).

Disclosure

The authors report no conflicts of interests in this work.

References

  • KönigJWellsJCaniPDHuman intestinal barrier function in health and diseaseClin Transl Gastroenterol2016710e19627763627
  • LechugaSIvanovAIDisruption of the epithelial barrier during intestinal inflammation: Quest for new molecules and mechanismsBiochim Biophys Acta18642017711831194
  • KatoTHondaYKuritaYLubiprostone improves intestinal permeability in humans, a novel therapy for the leaky gut: a prospective randomized pilot study in healthy volunteersPLoS One2017124e017562628410406
  • CzeruckaDDahanSMograbiBRossiBRampalPSaccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cellsInfect Immun200068105998600410992512
  • OdenwaldMATurnerJRIntestinal permeability defects: is it time to treat?Clin Gastroenterol Hepatol20131191075108323851019
  • GroschwitzKRHoganSPIntestinal barrier function: Molecular regulation and disease pathogenesisJ Allergy Clin Immunol20091241320 quiz 21–2219560575
  • JandhyalaSMTalukdarRSubramanyamCVuyyuruHSasikalaMNageshwar ReddyDRole of the normal gut microbiotaWorld J Gastroenterol201521298787880326269668
  • Rajilić-StojanovićMSmidtHde VosWMDiversity of the human gastrointestinal tract microbiota revisitedEnviron Microbiol2007992125213617686012
  • FreterRBricknerHFeketeJVickermanMMCareyKESurvival and implantation of Escherichia coli in the intestinal tractInfect Immun19833926867036339389
  • KamadaNChenGYInoharaNNúñezGControl of pathogens and pathobionts by the gut microbiotaNat Immunol201314768569023778796
  • UkenaSNSinghADringenbergUProbiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrityPLoS One2007212e130818074031
  • Garcia-GutierrezEMayerMJCotterPDNarbadAGut microbiota as a source of novel antimicrobialsGut Microbes201860121
  • SorgJASonensheinALBile salts and glycine as cogerminants for Clostridium difficile sporesJ Bacteriol200819072505251218245298
  • PengLLiZRGreenRSHolzmanIRLinJButyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayersJ Nutr200913991619162519625695
  • JohanssonMESjövallHHanssonGCThe gastrointestinal mucus system in health and diseaseNat Rev Gastroenterol Hepatol201310635236123478383
  • JohanssonMEVPhillipsonMPeterssonJVelcichAHolmLHanssonGCThe inner of the two MUC2 mucin-dependent mucus layers in colon is devoid of bacteriaProc Natl Acad Sci USA200810539150641506918806221
  • MergaYCampbellBJRhodesJMMucosal barrier, bacteria and inflammatory bowel disease: possibilities for therapyDig Dis201432447548324969297
  • TamuraAHayashiHImasatoMLoss of claudin-15, but not claudin-2, causes Na+ deficiency and glucose malabsorption in mouse small intestineGastroenterology2011140391392320727355
  • LeeSHIntestinal permeability regulation by tight junction: implication on inflammatory bowel diseasesIntest Res2015131111825691839
  • TercioloCDobricAOuaissiMSaccharomyces boulardii CNCM I-745 restores intestinal barrier integrity by regulation of E-cadherin recyclingJ Crohns Colitis2017118999101028333335
  • KimMAshidaHOgawaMYoshikawaYMimuroHSasakawaCBacterial interactions with the host epitheliumCell Host Microbe201081203520638639
  • AwadWHessCHessMPathogensEEnteric pathogens and their toxin-induced disruption of the intestinal barrier through alteration of tight junctions in chickensToxins (Basel)201792E6028208612
  • StierHBischoffSInfluence of Saccharomyces boulardii CNCM I-745 on the gut-associated immune systemClin Exp Gastroenterol2016926927927695355
  • HillDAArtisDIntestinal bacteria and the regulation of immune cell homeostasisAnnu Rev Immunol20102862366720192812
  • LallèsJPIntestinal alkaline phosphatase: novel functions and protective effectsNutr Rev2014722829424506153
  • FörsterCTight junctions and the modulation of barrier function in diseaseHistochem Cell Biol20081301557018415116
  • GuttmanJAFinlayBBTight junctions as targets of infectious agentsBiochim Biophys Acta178820094832841
  • KöhlerHSakaguchiTHurleyBPKaseBAReineckerHCMcCormickBASalmonella enterica serovar Typhimurium regulates intercellular junction proteins and facilitates transepithelial neutrophil and bacterial passageAm J Physiol Gastrointest Liver Physiol20072931G178G18717615177
  • ButsJPDe KeyserNEffects of Saccharomyces boulardii on intestinal mucosaDig Dis Sci20065181485149216838119
  • GraffSChaumeilJCBoyPLai-KuenRCharrueauCInfluence of pH conditions on the viability of Saccharomyces boulardii yeastJ Gen Appl Microbiol200854422122718802321
  • Edwards-IngramLGitshamPBurtonNGenotypic and physiological characterization of Saccharomyces boulardii, the Probiotic strain of Saccharomyces cerevisiaeAppl Environ Microbiol20077382458246717293506
  • FiettoJLAraújoRSValadãoFNMolecular and physiological comparisons between Saccharomyces cerevisiae and Saccharomyces boulardiiCan J Microbiol200450861562115467787
  • PardoSGalvagnoMACerruttiPStudies of viability and vitality after freezing of the probiotic yeast Saccharomyces boulardii: physiological preconditioning effectRev Iberoam Micol2009262155160 Spanish19631167
  • CarioEBarrier-protective function of intestinal epithelial Toll-like receptor 2Mucosal Immunol2008Suppl 1S62S6619079234
  • YuSGaoNCompartmentalizing intestinal epithelial cell Toll-like receptors for immune surveillanceCell Mol Life Sci201572173343335326001904
  • OppongGORapsinskiGJNewmanTNNishimoriJHBieseckerSGTükelÇEpithelial cells augment barrier function via activation of the Toll-like receptor 2/phosphatidylinositol 3-kinase pathway upon recognition of Salmonella enterica serovar typhimurium curli fibrils in the gutInfect Immun201381247848623208603
  • SzajewskaHGuarinoAHojsakIEuropean Society for Pediatric Gastroenterology, Hepatology, and NutritionUse of probiotics for management of acute gastroenteritis: a position paper by the ESPGHAN Working Group for probiotics and prebioticsJ Pediatr Gastroenterol Nutr201458453153924614141
  • McFarlandLVSystematic review and meta-analysis of Saccharomyces boulardii in adult patientsWorld J Gastroenterol201016182202222220458757
  • MoréMISwidsinskiASaccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis – a reviewClin Exp Gastroenterol2015823725526316791
  • BerkesJViswanathanVKSavkovicSDHechtGIntestinal epithelial responses to enteric pathogens: effects on the tight junction barrier, ion transport, and inflammationGut200352343945112584232
  • Ngendahayo MukizaCDubreuilJDEscherichia coli heat-stable toxin B impairs intestinal epithelial barrier function by altering tight junction proteinsInfect Immun20138182819282723716609
  • ShawkiAMcColeDFMechanisms of intestinal epithelial barrier dysfunction by adherent-invasive Escherichia coliCell Mol Gastroenterol Hepatol201731415028174756
  • Ugalde-SilvaPGonzalez-LugoONavarro-GarciaFTight junction disruption induced by type 3 secretion system effectors injected by enteropathogenic and enterohemorrhagic Escherichia coliFront Cell Infect Microbiol201668727606286
  • Shen-TuGKimHLiuMJohnson-HenryKCShermanPMProtein kinase C mediates enterohemorrhagic Escherichia coli O157:H7-induced attaching and effacing lesionsInfect Immun20148241648165624491575
  • DahanSDalmassoGImbertVPeyronJFRampalPCzeruckaDSaccharomyces boulardii interferes with enterohemorrhagic Escherichia coli-induced signaling pathways in T84 cellsInfect Immun200371276677312540556
  • WuXVallanceBABoyerLSaccharomyces boulardii ameliorates Citrobacter rodentium-induced colitis through actions on bacterial virulence factorsAm J Physiol Gastrointest Liver Physiol20082941G295G30618032474
  • ButsJPDekeyserNStilmantCDelemESmetsFSokalESaccharomyces boulardii produces in rat small intestine a novel protein phosphatase that inhibits Escherichia coli endotoxin by dephosphorylationPediatr Res2006601242916690953
  • HoyBGeppertTBoehmMDistinct roles of secreted HtrA proteases from gram-negative pathogens in cleaving the junctional protein and tumor suppressor E-cadherinJ Biol Chem201228713101151012022337879
  • MumyKLChenXKellyCPMcCormickBASaccharomyces boulardii interferes with Shigella pathogenesis by postinvasion signaling eventsAm J Physiol Gastrointest Liver Physiol20082943G599G60918032477
  • MartinsFSDalmassoGArantesRMInteraction of Saccharomyces boulardii with Salmonella enterica serovar typhimurium protects mice and modifies T84 cell response to the infectionPLoS One201051e892520111723
  • MartinsFSVieiraATElianSDInhibition of tissue inflammation and bacterial translocation as one of the protective mechanisms of Saccharomyces boulardii against Salmonella infection in miceMicrobes Infect201315427027923376166
  • TiagoFCMartinsFSSouzaELAdhesion to the yeast cell surface as a mechanism for trapping pathogenic bacteria by Saccharomyces probioticsJ Med Microbiol201261Pt 91194120722580913
  • Pontier-BresRProdonFMunroPModification of Salmonella typhimurium motility by the probiotic yeast strain Saccharomyces boulardiiPLoS One201273e3379622442723
  • Pontier-BresRMunroPBoyerLSaccharomyces boulardii modifies Salmonella typhimurium traffic and host immune responses along the intestinal tractPLoS One201498e10306925118595
  • SchmidtEKellySMvan der WalleCFTight junction modulation and biochemical characterisation of the zonula occludens toxin C-and N-terminiFEBS Lett2007581162974298017553496
  • CzeruckaDRampalPEffect of Saccharomyces boulardii on cAMP- and Ca2+ -dependent Cl− secretion in T84 cellsDig Dis Sci199944112359236810573387
  • CzeruckaDNanoJLBernasconiPRampalPResponse to cholera toxin of 2 epithelial intestinal cell lines. Effect of Saccharomyces boulardiiGastroenterol Clin Biol1989134383387 French2544474
  • BrandãoRLCastroIMBambirraEAIntracellular signal triggered by cholera toxin in Saccharomyces boulardii and Saccharomyces cerevisiaeAppl Environ Microbiol19986425645689464394
  • TafazoliFZengCQEstesMKMagnussonKESvenssonLNSP4 enterotoxin of rotavirus induces paracellular leakage in polarized epithelial cellsJ Virol20017531540154611152526
  • BuccigrossiVLaudieroGRussoCChloride secretion induced by rotavirus is oxidative stress-dependent and inhibited by Saccharomyces boulardii in human enterocytesPLoS One201496e9983024918938
  • SwidsinskiALoening-BauckeVKirschSDoerffelYFunctional biostructure of colonic microbiota (Central fermenting area, germinal stock area and separating mucus layer) in healthy subjects and patients with diarrhea treated with Saccharomyces boulardiiGastroentérologie Clinique et Biologique201034Suppl 1S79S92 French20889010
  • BinZYa-ZhengXZhao-HuiDBoCLi-RongJVandenplasYThe efficacy of Saccharomyces boulardii CNCM I-745 in addition to standard Helicobacter pylori eradication treatment in childrenPediatr Gastroenterol Hepatol Nutr2015181172225866729
  • KabbaniTAPallavKDowdSEProspective randomized controlled study on the effects of Saccharomyces boulardii CNCM I-745 and amoxicillin-clavulanate or the combination on the gut microbiota of healthy volunteersGut Microbes201781173227973989
  • JumpRLClostridium difficile infection in older adultsAging Health20139440341424955106
  • NusratAvon Eichel-StreiberCTurnerJRVerkadePMadaraJLParkosCAClostridium difficile toxins disrupt epithelial barrier function by altering membrane microdomain localization of tight junction proteinsInfect Immun20016931329133611179295
  • HechtGPothoulakisCLaMontJTMadaraJLClostridium difficile toxin A perturbs cytoskeletal structure and tight junction permeability of cultured human intestinal epithelial monolayersJ Clin Invest1988825151615243141478
  • BeaugerieLFlahaultABarbutFStudy GroupAntibiotic-associated diarrhoea and Clostridium difficile in the communityAliment Pharmacol Ther200317790591212656693
  • MassotJSanchezOCouchyRAstoinJParodiALBacterio-pharmacological activity of Saccharomyces boulardii in clindamycin-induced colitis in the hamsterArzneimittelforschung19843477947976541916
  • ToothakerRDElmerGWPrevention of clindamycin-induced mortality in hamsters by Saccharomyces boulardiiAntimicrob Agents Chemother19842645525566517545
  • CorthierGDubosFDucluzeauRPrevention of Clostridium difficile induced mortality in gnotobiotic mice by Saccharomyces boulardiiCan J Microbiol198632118948963815159
  • ElmerGWMcFarlandLVSuppression by Saccharomyces boulardii of toxigenic Clostridium difficile overgrowth after vancomycin treatment in hamstersAntimicrob Agents Chemother19873111291313566236
  • ButsJPBernasconiPVaermanJPDiveCStimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardiiDig Dis Sci19903522512562302983
  • CastagliuoloILaMontJTNikulassonSTPothoulakisCSaccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileumInfect Immun19966412522552328945570
  • CastagliuoloIRieglerMFValenickLLaMontJTPothoulakisCSaccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosaInfect Immun19996713023079864230
  • SougioultzisSSimeonidisSBhaskarKRSaccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expressionBiochem Biophys Res Commun20063431697616529714
  • HalpernMDDenningPWThe role of intestinal epithelial barrier function in the development of NECTissue Barriers201531–2e100070725927016
  • RodríguezJMMurphyKStantonCThe composition of the gut microbiota throughout life, with an emphasis on early lifeMicrob Ecol Health Dis2015262605025651996
  • Gomez de AgüeroMGanal-VonarburgSCFuhrerTThe maternal microbiota drives early postnatal innate immune developmentScience201635162791296130226989247
  • DigiulioDBRomeroRAmoganHPMicrobial prevalence, diversity and abundance in amniotic fluid during preterm labor: a molecular and culture-based investigationPLoS One200838e305618725970
  • FlassTTongSFrankDNIntestinal lesions are associated with altered intestinal microbiome and are more frequent in children and young adults with cystic fibrosis and cirrhosisPLoS One2015102e011696725658710
  • JiménezEFernándezLMarínMLIsolation of commensal bacteria from umbilical cord blood of healthy neonates born by cesarean sectionCurr Microbiol200551427027416187156
  • AjslevTAAndersenCSGamborgMSørensenTIJessTChildhood overweight after establishment of the gut microbiota: the role of delivery mode, pre-pregnancy weight and early administration of antibioticsInt J Obes (Lond)201135452252921386800
  • YassourMVatanenTSiljanderHXavierRJDIABIMMUNE Study GroupNatural history of the infant gut microbiome and impact of antibiotic treatment on bacterial strain diversity and stabilitySci Transl Med20168343343ra81
  • JohnsonCCOwnbyDRThe infant gut bacterial microbiota and risk of pediatric asthma and allergic diseasesTransl Res2017179607027469270
  • BerdingKDonovanSMDiet can impact microbiota composition in children with autism spectrum disorderFrontiers in neuroscience201812
  • JakaitisBMDenningPWHuman breast milk and the gastrointestinal innate immune systemClin Perinatol201441242343524873841
  • WestCERenzHJenmalmMCThe gut microbiota and inflammatory noncommunicable diseases: associations and potentials for gut microbiota therapiesJournal of Allergy and Clinical Immunology201511135131325567038
  • SjögrenYMTomicicSLundbergAInfluence of early gut microbiota on the maturation of childhood mucosal and systemic immune responsesClin Exp Allergy200939121842185119735274
  • RoundJLMazmanianSKInducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiotaProc Natl Acad Sci USA201010727122041220920566854
  • DemirelGErdeveOCelikIHDilmenUSaccharomyces boulardii for prevention of necrotizing enterocolitis in preterm infants: a randomized, controlled studyActa Paediatrica201310212e560e56524028629
  • DrosteJHWieringaMHWeylerJJNelenVJVermeirePAVan BeverHPDoes the use of antibiotics in early childhood increase the risk of asthma and allergic disease?Clin Exp Allergy2000301115481553
  • OngM-SUmetsuDTMandlKDConsequences of antibiotics and infections in infancy: bugs, drugs, and wheezingAnn Allergy Asthma Immunol20141125441445.e124631182
  • BaileyLCForrestCBZhangPRichardsTMLivshitsADeRussoPAAssociation of antibiotics in infancy with early childhood obesityJAMA Pediatr2014168111063106925265089
  • CukrowskaBSowińskaABierłaJBCzarnowskaERybakAGrzybowska-ChlebowczykUIntestinal epithelium, intraepithelial lymphocytes and the gut microbiota - Key players in the pathogenesis of celiac diseaseWorld J Gastroenterol201723427505751829204051
  • WestCERenzHJenmalmMCin-FLAME Microbiome Interest GroupThe gut microbiota and inflammatory noncommunicable diseases: associations and potentials for gut microbiota therapiesJ Allergy Clin Immunol20151351313 quiz 1425567038
  • BjörksténBSeppEJulgeKVoorTMikelsaarMAllergy development and the intestinal microflora during the first year of lifeJ Allergy Clin Immunol2001108451652011590374
  • HarbisonJERoth-SchulzeAJBarrySCGut microbiome dysbiosis and increased intestinal permeability in Australian children with islet autoimmunity and type 1 diabetesDiabetes201867Suppl 1230-OR2300
  • Leiva-GeaISánchez-AlcoholadoLMartín-TejedorBGut microbiota differs in composition and functionality between children with type 1 diabetes and MODY2 and healthy control subjects: a case-control studyDiabetes Care201841112385239530224347
  • LiXAtkinsonMAThe role for gut permeability in the pathogenesis of type 1 diabetes–a solid or leaky concept?Pediatr Diabetes201516748549226269193
  • MaffeisCMartinaACorradiMAssociation between intestinal permeability and faecal microbiota composition in Italian children with beta cell autoimmunity at risk for type 1 diabetesDiabetes Metab Res Rev201632770070926891226
  • AbrahamssonTRJakobssonHEAnderssonAFBjörksténBEngstrandLJenmalmMCLow diversity of the gut microbiota in infants with atopic eczemaJ Allergy Clin Immunol20121292434440e1-e222153774
  • OzkanTBSahinEErdemirGBudakFEffect of Saccharomyces boulardii in children with acute gastroenteritis and its relationship to the immune responseJ Int Med Res200735220121217542407
  • CaetanoJAParamésMTBaboMJImmunopharmacological effects of Saccharomyces boulardii in healthy human volunteersInt J Immunopharmacol1986832452593733298
  • DelzenneNMNeyrinckAMCaniPDGut microbiota and metabolic disorders: how prebiotic can work?Br J Nutr2013109Suppl 2S81S8523360884
  • LiuLSteinleJJToll-like receptor 4 regulates insulin signal transduction in retinal Müller cellsGrowth Factors201735623423829490521
  • SzaboGGut–Liver axis in alcoholic liver diseaseGastroenterology20151481303625447847
  • MieleLValenzaVLa TorreGIncreased intestinal permeability and tight junction alterations in nonalcoholic fatty liver diseaseHepatology20094961877188719291785
  • BaumgartDCSandbornWJInflammatory bowel disease: clinical aspects and established and evolving therapiesLancet200736995731641165717499606
  • CosnesJGower-RousseauCSeksikPCortotAEpidemiology and natural history of inflammatory bowel diseasesGastroenterology201114061785179421530745
  • RajcaSGrondinVLouisEAlterations in the intestinal micro-biome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn’s diseaseInflamm Bowel Dis201420697898624788220
  • ChangJLeongRWWasingerVCIpMYangMPhanTGImpaired intestinal permeability contributes to ongoing bowel symptoms in patients with inflammatory bowel disease and mucosal healingGastroenterology20171533723731.e128601482
  • ZbarAPSimopoulosCKarayiannakisAJCadherins: an integral role in inflammatory bowel disease and mucosal restitutionJ Gastroenterol200439541342115175938
  • BourreilleACadiotGLe DreauGFLORABEST Study GroupSaccharomyces boulardii does not prevent relapse of Crohn’s diseaseClin Gastroenterol Hepatol201311898298723466709
  • Garcia VilelaEDe Lourdes De Abreu FerrariMOswaldo da Gama TorresHInfluence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn’s disease in remissionScand J Gastroenterol200843784284818584523
  • CanoniciASiretCPellegrinoESaccharomyces boulardii improves intestinal cell restitution through activation of the α2β1 integrin collagen receptorPLoS One201163e1842721483797
  • CanoniciAPellegrinoESiretCSaccharomyces boulardii improves intestinal epithelial cell restitution by inhibiting αvβ5 integrin activation statePLoS One201279e4504723028753
  • LovellRMFordACGlobal prevalence of and risk factors for irritable bowel syndrome: a meta-analysisClin Gastroenterol Hepatol2012107712721.e422426087
  • MearinFBeLChangLBowel disordersGastroenterology2016150613931407
  • PicheTBarbaraGAubertPImpaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediatorsGut200958219620118824556
  • Bertiaux-VandaëleNYoumbaSBBelmonteLThe expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtypeAm J Gastroenterol2011106122165217322008894
  • AbbasZYakoobJJafriWCytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: a randomized trialEur J Gastroenterol Hepatol201426663063924722560
  • JumpertzRLeDSTurnbaughPJEnergy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humansAm J Clin Nutr2011941586521543530
  • ZhangYJLiSGanRYZhouTXuDPLiHBImpacts of gut bacteria on human health and diseasesInt J Mol Sci20151647493751925849657
  • ZinöckerMLindsethIThe western diet–microbiomehost interaction and its role in metabolic diseaseNutrients2018103E36529562591
  • GenserLPoitouCÉB-LAlteration of intestinal permeability: the missing link between gut microbiota modifications and inflammation in obesity?Med Sci (Paris)201632546146927225918
  • KimKAGuWLeeIAJohEHKimDHHigh fat diet-induced gut microbiota exacerbates inflammation and obesity in mice via the TLR4 signaling pathwayPLoS One2012710e4771323091640
  • HamiltonMKBoudryGLemayDGRaybouldHEChanges in intestinal barrier function and gut microbiota in high-fat diet-fed rats are dynamic and region dependentAm J Physiol Gastrointest Liver Physiol201530810G840G85125747351
  • EverardAMatamorosSGeurtsLDelzenneNMCaniPDSaccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db miceMBio201453e010110101424917595
  • SchnablBBrennerDAInteractions between the intestinal microbiome and liver diseasesGastroenterology201414661513152424440671
  • ChangBSangLWangYTongJWangBThe role of FOXO4 in the relationship between alcohol-induced intestinal barrier dysfunction and liver injuryInt J Mol Med201331356957623292333
  • KarahanNIşlerMKoyuAEffects of probiotics on methionine choline deficient diet-induced steatohepatitis in ratsTurk J Gastroenterol201223211012122706738
  • SchneiderSMGirard-PipauFFilippiJEffects of Saccharomyces boulardii on fecal short-chain fatty acids and microflora in patients on long-term total enteral nutritionWorld J Gastroenterol200511396165616916273644
  • FengYSunXYangHTeitelbaumDHDissociation of E-cadherin and beta-catenin in a mouse model of total parenteral nutrition: a mechanism for the loss of epithelial cell proliferation and villus atrophyJ Physiol2009587Pt 364165419064618
  • NazliAChanODobson-BelaireWNExposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocationPLoS Pathog201064e100085220386714
  • Villar-GarcíaJHernándezJJGüerri-FernándezREffect of probiotics (Saccharomyces boulardii) on microbial translocation and inflammation in HIV-treated patients: a double-blind, randomized, placebo-controlled trialJ Acquir Immune Defic Syndr201568325626325469528
  • Al-SadiRYeDBoivinMInterleukin-6 modulation of intestinal epithelial tight junction permeability is mediated by JNK pathway activation of claudin-2 genePLoS One201493e8534524662742
  • MutluEAKeshavarzianALosurdoJA compositional look at the human gastrointestinal microbiome and immune activation parameters in HIV infected subjectsPLoS Pathog2014102e100382924586144
  • CapaldoCTNusratACytokine regulation of tight junctionsBiochim Biophys Acta178820094864871
  • Villar-GarcíaJGüerri-FernándezRMoyaAImpact of probi-otic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: a double-blind, randomised, placebo-controlled trialPLoS One2017124e017380228388647
  • BrevesGFaulKSchröderBHolstHCasparyWFSteinJApplication of the colon-simulation technique for studying the effects of Saccharomyces boulardii on basic parameters of porcine cecal microbial metabolism disturbed by clindamycinDigestion200061319320010773725